{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "KYMR",
  "name": "Kymera Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/KYMR/",
  "json_url": "https://orbyd.app/dossiers/KYMR.json",
  "status": "RECENTLY_EXITED",
  "current_conviction": "LOW",
  "graded_conviction": "NONE",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing, stretched theme better bought on a pullback to the $100 shelf than chased into the catalyst gap.",
  "invalidation_trigger": "A weekly close below $100 forfeits the post-BROADEN2 breakout base; secondary confirmation if the I&I/derm M&A theme goes quiet (no follow-on bid after AbbVie–Apogee) alongside a second analyst downgrade following RBC's 7/13 cut.",
  "catalyst_date": "2026-08-05",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-07-02",
  "invalidation_fired": false,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Pre-revenue on products: all reported revenue is collaboration and milestone income (Q1 2026: $34.37M), so the quarterly revenue line is lumpy and is not a demand signal.",
    "BROADEN2 topline is guided \"by year-end 2026\" with no fixed date and no pre-announcement, so it can print in any week of Q4.",
    "June–July 2026 insider and venture-fund sales ran through Rule 10b5-1 plans adopted in December 2025 and on 2026-03-24, so they were pre-scheduled rather than discretionary.",
    "Short interest is structurally elevated at 15.19% of a 65.16M float with 7.75 days to cover, so single headlines amplify in both directions.",
    "82.26M shares outstanding against a 65.16M float; the gap is restricted and insider stock that reaches the market through filed 10b5-1 plans.",
    "Sanofi is both a Kymera collaboration partner and the funder of Recludix's rival oral STAT6 program, so Sanofi news can cut in either direction."
  ],
  "body_markdown": "## Current Thesis\n\nThe leg an investor is buying has not changed: KT-621, a once-daily oral STAT6 degrader aimed at the IL-4/IL-13 axis that injectable biologics own today, re-rated on 2026-06-25 when Kymera completed BROADEN2 Phase 2b enrollment nearly six months early and pulled topline forward to \"by year-end 2026\" — three days after AbbVie agreed to buy Apogee Therapeutics for $10.9B on 2026-06-22. What has advanced since the last note is that the level the frame hung on was tested and held. Shares traded to $99.52 intraday on 2026-08-03 and closed $100.31; on 2026-08-04 they closed $104.39, up $4.08 (+4.07%). That session was a sector move first — XBI closed 2026-08-04 at $151.88, +3.10%. The rising 50-day average has come up to $98.93 and the 200-day to $82.59. Into that, Q2 results land before the open on 2026-08-05 with a webcast at 8:30 a.m. ET, carrying no BROADEN2 data: the print settles Q2 burn against the $1.55B of cash, equivalents and investments held at 2026-03-31, tests whether \"by year-end 2026\" gets narrowed to a stated quarter or month, and gives Terence Rooney his first public call since the 2026-07-27 CMO appointment. The event that actually re-prices the equity is still undated inside Q4.\n\n## Bull Case\n\n- BROADEN2 enrollment completed 2026-06-25 nearly six months ahead of plan, moving topline in from mid-2027: roughly 200 patients aged 12–75 with moderate-to-severe atopic dermatitis, three KT-621 doses versus placebo over 16 weeks, primary endpoint percent change from baseline in EASI at Week 16, with AD Phase 3 initiation guided by mid-2027 subject to regulator discussions.\n- The base the June advance built on was defended in the tape. The 2026-08-03 session low of $99.52 sat within a dollar of the 50-day average, and the following session closed $104.39.\n- Financing pressure is absent into the readout. Q1 2026 results (2026-04-30) put cash, equivalents and investments at $1.55B as of 2026-03-31 with runway into 2029, sized to complete both KT-621 Phase 2b trials, fund a large part of the first AD Phase 3, and carry KT-579 through initial proof of concept.\n- A second dated shot sits in the same half-year: KT-579, an oral IRF5 degrader, has single- and multiple-ascending-dose Phase 1 data guided 2H-2026, with a patient proof-of-concept trial planned, likely in lupus. Guggenheim's 2026-07-28 raise to $135 rests on that program.\n- Published targets remain above the tape: $127.18 average across 24 analysts as of 2026-08-04, spanning $97 to $155, with Mizuho $140 (2026-07-16), Guggenheim $135 (2026-07-28) and Deutsche Bank $120 (2026-07-30).\n- FDA Fast Track is in hand for both lead indications — atopic dermatitis (December 2025) and moderate-to-severe eosinophilic asthma (2026-04-13) — so the regulatory pathway is not the open question; the Week-16 EASI number is.\n\n## Bear Case\n\n- The rating cycle turned three weeks before the print and has not turned back. RBC cut to Sector Perform on 2026-07-13; Deutsche Bank initiated at Hold with a $120 target on 2026-07-30. The last raise, Guggenheim to $135 on 2026-07-28, was written about KT-579 rather than the atopic-dermatitis asset.\n- Newsflow has gone quiet ahead of the print. Kymera's most recent press release is dated 2026-07-28 and is a scheduling notice; the last SEC filing is dated 2026-07-27. The 2026-08-04 advance therefore carried no company-specific disclosure behind it.\n- Executive selling ran through July at prices above the current tape. Both ran under a 10b5-1 plan adopted 2026-03-24.\n- Part of June's demand was mechanical. Kymera was added to Russell indices at the late-June reconstitution in the same window as the 2026-06-25 enrollment release, so the 16.9% single-session move blended index flow with news.\n- The strategic-bid leg has produced nothing since. AbbVie–Apogee ($10.9B, 2026-06-22) is still the only dermatology/I&I transaction anchoring the read-through; Merck KGaA's $11.3B Bio-Techne deal announced in July is life-science tools and does not extend it.\n- Price is 19.7% below the 2026-06-25 spike high of $130.05 more than six weeks later, and no session since has retested that high.\n\n## Setup & Price Structure\n\nWhere the narrative sits: **MATURING** — well known, still working, moderating flow. Dating that: the upgrade cycle peaked between 2026-06-25 and 2026-06-30 (Canaccord $129, B. Riley $155, Truist $136, BofA $125) and turned with RBC's 2026-07-13 downgrade; the last substantive company release is 2026-07-27. Price has held a range instead of extending — $104.39 on 2026-08-04 against $130.05 on 2026-06-25.\n\nStructure: the $98–$100 zone is the whole base. It was tested on 2026-08-03 (low $99.52, close $100.31) and reclaimed on 2026-08-04 (+4.07% to $104.39). The rising 50-day average at $98.93 now sits inside that same zone, so the round number and the trend line resolve together — a break is one event, not two. The 200-day at $82.59 is 20.9% below the last close and is not in play on any near-term move.\n\nCrowding and positioning, as observables:\n\n- Short interest 9.90M shares, 15.19% of the 65.16M float, 7.75 days to cover.\n- Price sits 5.5% above the rising 50-day average and 26.4% above the 200-day. Beta 1.96.\n- The earnings date is not approaching — it is the same day. Results are due before the open on 2026-08-05.\n- Insider supply is documented and pre-scheduled: CEO sales on 2026-07-01 and 2026-07-07 under a plan adopted 2026-03-24, plus venture-fund Form 144 and Form 4 activity clustered 2026-06-24 through 2026-07-07. 82.26M shares outstanding against a 65.16M float leaves 17.1M shares of restricted and insider stock that reaches the market through filed plans.\n- Sell-side dispersion is wide: $97 low to $155 high across 24 analysts, roughly a 60% spread on the same asset.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-11 (est.)** — Q2 2026 Form 10-Q: ATM utilisation, any new shelf registration, and quarterly burn against 82.26M shares outstanding.\n- **~2026-08-11 (est.)** — semi-monthly short-interest publication for the 2026-07-31 settlement date, read against 9.90M shares short and 7.75 days to cover.\n- **~2026-08-26 (est.)** — short-interest publication for the 2026-08-14 settlement date; the first read on whether the print added or removed short exposure.\n- Nothing else in the window carries a date. KT-579 Phase 1 SAD/MAD data is guided 2H-2026 with no date; BROADEN2 topline is guided by 2026-12-31 with no pre-announcement. Either can land in any week.\n\n## Elapsed catalysts\n\n- **2026-08-05** — Q2 2026 results before the open, webcast 8:30 a.m. ET. Carries no BROADEN2 data. What it can move: the wording of the \"by year-end 2026\" topline window, Q2 burn against the $1.55B held at 2026-03-31, and the first public remarks from CMO Terence Rooney since his 2026-07-27 appointment. Consensus is -$0.7126 EPS on $32.78M revenue. *(passed 4d ago)*\n\n## What Would Change Our Mind\n\nThe structure that has to hold is the $98–$100 shelf the June advance built, now with the rising 50-day average climbed up into it at $98.93. Losing that zone forfeits the entire post-BROADEN2 base and puts the next reference at the 200-day, more than twenty percent lower. Stated gradeably: a weekly close below $98 ends this leg.\n\nTwo non-price conditions do comparable damage. First, the 2026-08-05 call leaving \"by year-end 2026\" un-narrowed and adding no dated interim event — that leaves roughly four months of calendar with nothing to price, and it is the condition under which this theme slides from MATURING toward SATURATED. Second, evidence that the June re-rating was flow rather than franchise: a further neutral rating following RBC (2026-07-13) and Deutsche Bank (2026-07-30) with no dermatology or I&I acquisition announced through Q3 2026 to follow AbbVie–Apogee.\n\nWhat would strengthen the case instead: a topline window narrowed to a stated month or quarter on the 2026-08-05 call; a KT-579 Phase 1 disclosure clearing the degradation bar the study was designed around, which turns a single-asset story into two; or a daily close back above $115 on expanding volume, reclaiming both RBC's raised target level and the upper half of the June range.\n\n## Correlation Notes\n\n- Sector beta is doing most of the recent work. XBI closed 2026-08-04 at $151.88, +3.10%, on the same session KYMR gained 4.07%. At a beta of 1.96, that single-name move is roughly what the tape delivered. XBI's trailing-year total return is 77.56%; KYMR's 52-week change is +142.99%.\n- Sanofi sits on both sides of the trade. It pays Kymera milestones — $20M triggered 2026-06-09 on first dosing of KT-485 (SAR447971) — and separately funds Recludix's oral STAT6 inhibitor REX-8756 (SAR448755), which began Phase 1 dosing in January 2026. A clean Recludix Phase 1 disclosure reads negative for KT-621's competitive runway and positive for Sanofi's degrader spend at the same time.\n- Dupilumab-franchise datapoints from Sanofi and Regeneron set the comparator BROADEN2 is judged against: the EASI response rates injectables already deliver define the hurdle for KT-621's Week-16 primary endpoint, so type-2 biologic trends move the perceived bar with no KYMR news attached.\n- The M&A read-through channel runs through large-cap I&I acquirers. AbbVie–Apogee on 2026-06-22 is what re-rated the group; any subsequent dermatology or respiratory takeout re-opens that channel, and a quiet Q3 closes it.\n- Index membership adds a non-fundamental flow term after the late-June Russell reconstitution: rebalance dates now move the stock independently of KT-621.",
  "first_seen": "2026-06-26",
  "last_analyzed": "2026-08-05T04:06:02+00:00",
  "last_synthesized": "2026-08-05",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}